OID|ValueSetName|NumberOfCodes
1.3.6.1.4.1.33895.1.3.0.45|Comfort Measures |4
2.16.840.1.113762.1.4.1|ONC Administrative Sex|3
2.16.840.1.113762.1.4.1021.10|Warfarin-only ingredient specific|1
2.16.840.1.113762.1.4.1021.11|Injectable factor Xa inhibitor for VTE prophylaxis ingredient specific|1
2.16.840.1.113762.1.4.1021.12|Low Molecular Weight Heparin for VTE prophylaxis ingredient specific|3
2.16.840.1.113762.1.4.1021.13|Unfractionated Heparin for VTE prophylaxis ingredient specific|1
2.16.840.1.113762.1.4.1021.3|Aspirin ingredient specific|1
2.16.840.1.113762.1.4.1021.4|Parenteral anticoagulant ingredient specific|8
2.16.840.1.113762.1.4.1021.6|t-PA ingredient specific|1
2.16.840.1.113762.1.4.1021.7|Statin ingredient specific|10
2.16.840.1.113762.1.4.1021.8|Antithrombotic ingredient specific|15
2.16.840.1.113762.1.4.1021.9|Anticoagulant ingredient specific|11
2.16.840.1.113762.1.4.1045.14|Time of Symptom Onset|1
2.16.840.1.113762.1.4.1045.15|Intravenous Thrombolytic (t-PA) Therapy|1
2.16.840.1.113762.1.4.1045.18|Rehabilitation Assessment|16
2.16.840.1.113762.1.4.1045.19|Rehabilitation Therapy|536
2.16.840.1.113762.1.4.1045.21|Intravenous or Intra-arterial Thrombolytic (t-PA) Therapy|2
2.16.840.1.113762.1.4.1045.24|Prothrombin Time|2
2.16.840.1.113762.1.4.1045.25|Partial Thromboplastin Time|1
2.16.840.1.113762.1.4.1045.26|Estimated Gestational Age at Delivery|1
2.16.840.1.113762.1.4.1045.27|Cornual Ectopic Pregnancy|1
2.16.840.1.113762.1.4.1045.28|Time of Delivery|1
2.16.840.1.113762.1.4.1045.29|Feeding Intention-Breast|1
2.16.840.1.113762.1.4.1045.3|IV Ceftriaxone|5
2.16.840.1.113762.1.4.1045.31|Other Anticoagulants for AMI|7
2.16.840.1.113762.1.4.1045.32|Hospital Measures-PACU|3
2.16.840.1.113762.1.4.1045.36|NSTEMI|13
2.16.840.1.113762.1.4.1045.39|Low Dose Unfractionated Heparin for VTE Prophylaxis|2
2.16.840.1.113762.1.4.1045.41|Glycoprotein IIb/IIIa Inhibitors|5
2.16.840.1.113762.1.4.1045.45|Thrombocytopenia|54
2.16.840.1.113762.1.4.1045.47|Estimated Gestational Age at Birth|1
2.16.840.1.113762.1.4.1045.5|IM or PO Antimicrobial medications|286
2.16.840.1.113762.1.4.1045.52|Laparoscopic Procedures|421
2.16.840.1.113762.1.4.1045.55|Oxytocin|8
2.16.840.1.113762.1.4.1045.56|Dinoprostone|1
2.16.840.1.113762.1.4.1045.57|Artificial Rupture of Membranes|2
2.16.840.1.113762.1.4.1045.6|IM or PO route|12
2.16.840.1.113762.1.4.1045.67|PCI|84
2.16.840.1.113762.1.4.1045.69|Endotrachael Intubation|15
2.16.840.1.113762.1.4.1045.7|IV Cefazolin|7
2.16.840.1.113762.1.4.1045.74|Indwelling urinary catheter|10
2.16.840.1.113762.1.4.1045.77|Tracheostomy care|2
2.16.840.1.113762.1.4.1045.8|IV Cefuroxime|6
2.16.840.1.113762.1.4.1045.84|Reason For Admission to ICU due to Pneumonia|85
2.16.840.1.113762.1.4.1046.6|Liveborn Newborn Born in Hospital|25
2.16.840.1.113762.1.4.1078.5|Delivery - Procedure|160
2.16.840.1.113762.1.4.1080.2|Face to Face Interaction - No ED|15
2.16.840.1.113883.3.117.1.7.1.131|Asthma Management Plan|1
2.16.840.1.113883.3.117.1.7.1.132|Discharged to Rehabilitation Facility|1
2.16.840.1.113883.3.117.1.7.1.134|Oral Factor Xa Inhibitor for VTE Prophylaxis|5
2.16.840.1.113883.3.117.1.7.1.136|Perforation of Uterus|6
2.16.840.1.113883.3.117.1.7.1.137|Uterine Window|1
2.16.840.1.113883.3.117.1.7.1.138|Uterine Rupture|9
2.16.840.1.113883.3.117.1.7.1.139|Aspirin Allergen|114
2.16.840.1.113883.3.117.1.7.1.14|Principal|1
2.16.840.1.113883.3.117.1.7.1.2|SCIP Major Surgical Procedure|5783
2.16.840.1.113883.3.117.1.7.1.200|Anticoagulant Therapy|86
2.16.840.1.113883.3.117.1.7.1.201|Antithrombotic Therapy|160
2.16.840.1.113883.3.117.1.7.1.202|Atrial Fibrillation/Flutter|26
2.16.840.1.113883.3.117.1.7.1.203|Atrial Ablation|11
2.16.840.1.113883.3.117.1.7.1.205|Direct Thrombin Inhibitor|6
2.16.840.1.113883.3.117.1.7.1.207|Discharged to Health Care Facility for Hospice Care|1
2.16.840.1.113883.3.117.1.7.1.209|Discharged to Home for Hospice Care|1
2.16.840.1.113883.3.117.1.7.1.211|Injectable Factor Xa Inhibitor for VTE Prophylaxis|6
2.16.840.1.113883.3.117.1.7.1.212|Hemorrhagic Stroke|69
2.16.840.1.113883.3.117.1.7.1.213|INR|5
2.16.840.1.113883.3.117.1.7.1.214|Intermittent pneumatic compression devices (IPC)|3
2.16.840.1.113883.3.117.1.7.1.215|LDL-c|6
2.16.840.1.113883.3.117.1.7.1.217|Lipid-lowering Agent|137
2.16.840.1.113883.3.117.1.7.1.218|Unfractionated Heparin|8
2.16.840.1.113883.3.117.1.7.1.219|Low Molecular Weight Heparin for VTE Prophylaxis|22
2.16.840.1.113883.3.117.1.7.1.222|Intravenous route|3
2.16.840.1.113883.3.117.1.7.1.223|Subcutaneous route|1
2.16.840.1.113883.3.117.1.7.1.225|Statin|70
2.16.840.1.113883.3.117.1.7.1.226|Thrombolytic (t-PA) Therapy|1
2.16.840.1.113883.3.117.1.7.1.230|Venous foot pumps (VFP)|1
2.16.840.1.113883.3.117.1.7.1.232|Warfarin|9
2.16.840.1.113883.3.117.1.7.1.247|Ischemic Stroke|128
2.16.840.1.113883.3.117.1.7.1.25|Single Live Birth|1
2.16.840.1.113883.3.117.1.7.1.253|Clinical Pathway Protocol|1
2.16.840.1.113883.3.117.1.7.1.255|General Surgery|3731
2.16.840.1.113883.3.117.1.7.1.256|Graduated compression stockings (GCS)|47
2.16.840.1.113883.3.117.1.7.1.257|Gynecological Surgery|189
2.16.840.1.113883.3.117.1.7.1.258|Hip Fracture Surgery|16
2.16.840.1.113883.3.117.1.7.1.259|Hip Replacement Surgery|101
2.16.840.1.113883.3.117.1.7.1.26|Single Liveborn Newborn Born in Hospital|4
2.16.840.1.113883.3.117.1.7.1.260|Intracranial Neurosurgery|385
2.16.840.1.113883.3.117.1.7.1.261|Knee Replacement Surgery|76
2.16.840.1.113883.3.117.1.7.1.262|Mental Disorders|2401
2.16.840.1.113883.3.117.1.7.1.263|Obstetrics|2043
2.16.840.1.113883.3.117.1.7.1.264|Obstetrics VTE|94
2.16.840.1.113883.3.117.1.7.1.266|Parenteral Anticoagulant|43
2.16.840.1.113883.3.117.1.7.1.267|Platelet Count|8
2.16.840.1.113883.3.117.1.7.1.269|National Institute of Health Stroke Scale|1
2.16.840.1.113883.3.117.1.7.1.27|Dietary Intake Other than Breast Milk|9
2.16.840.1.113883.3.117.1.7.1.271|Asthma|66
2.16.840.1.113883.3.117.1.7.1.272|Urological Surgery|398
2.16.840.1.113883.3.117.1.7.1.276|VTE Diagnostic Test|146
2.16.840.1.113883.3.117.1.7.1.277|VTE Suspected|2
2.16.840.1.113883.3.117.1.7.1.278|Treatment Adjusted by Protocol|1
2.16.840.1.113883.3.117.1.7.1.279|Venous Thromboembolism|137
2.16.840.1.113883.3.117.1.7.1.281|Labor|6
2.16.840.1.113883.3.117.1.7.1.282|Cesarean Section|25
2.16.840.1.113883.3.117.1.7.1.286|Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation|888
2.16.840.1.113883.3.117.1.7.1.288|Medical Induction of Labor|12
2.16.840.1.113883.3.117.1.7.1.292|Emergency Department Visit|1
2.16.840.1.113883.3.117.1.7.1.295|Decision to Admit to Hospital Inpatient|3
2.16.840.1.113883.3.117.1.7.1.299|Psychiatric/Mental Health Patient|2232
2.16.840.1.113883.3.117.1.7.1.30|Breast Milk|1
2.16.840.1.113883.3.117.1.7.1.301|Medication Compliance Education|9
2.16.840.1.113883.3.117.1.7.1.302|Vitamin K Dietary Management|1
2.16.840.1.113883.3.117.1.7.1.303|Follow-up Monitoring|3
2.16.840.1.113883.3.117.1.7.1.304|Adverse Drug Reactions Education|2
2.16.840.1.113883.3.117.1.7.1.305|ICU Admission or Transfer|9
2.16.840.1.113883.3.117.1.7.1.308|Left Against Medical Advice|1
2.16.840.1.113883.3.117.1.7.1.309|Patient Expired|1
2.16.840.1.113883.3.117.1.7.1.35|Galactosemia|3
2.16.840.1.113883.3.117.1.7.1.357|VTE Risk Assessment|1
2.16.840.1.113883.3.117.1.7.1.372|Complication Mainly Related to Pregnancy|103
2.16.840.1.113883.3.117.1.7.1.375|Complication of the Puerperium|66
2.16.840.1.113883.3.117.1.7.1.377|Activation of Emergency Medical System Education|2
2.16.840.1.113883.3.117.1.7.1.378|Instructions for Follow Up After Discharge|2
2.16.840.1.113883.3.117.1.7.1.379|Prescribed Medications Education|2
2.16.840.1.113883.3.117.1.7.1.38|Parenteral Infusion|8
2.16.840.1.113883.3.117.1.7.1.380|Risk Factors Education|1
2.16.840.1.113883.3.117.1.7.1.381|Warning Signs and Symptoms Education|1
2.16.840.1.113883.3.117.1.7.1.391|Normal Delivery and Other Indications for Care|88
2.16.840.1.113883.3.117.1.7.1.397|Complication Mainly in the Course of Labor and Delivery|82
2.16.840.1.113883.3.117.1.7.1.400|Low Risk|2
2.16.840.1.113883.3.117.1.7.1.401|Delivery Procedures|80
2.16.840.1.113883.3.117.1.7.1.407|VTE Confirmed|52
2.16.840.1.113883.3.117.1.7.1.412|Medical Contraindication|14
2.16.840.1.113883.3.117.1.7.1.413|Recommendation not to change diet|1
2.16.840.1.113883.3.117.1.7.1.414|Drug Interactions Education|2
2.16.840.1.113883.3.117.1.7.1.415|Written Information Given|1
2.16.840.1.113883.3.117.1.7.1.416|INR Monitoring Education|1
2.16.840.1.113883.3.117.1.7.1.417|Baseline State|1
2.16.840.1.113883.3.117.1.7.1.421|Classical Cesarean Section|5
2.16.840.1.113883.3.117.1.7.1.422|Myomectomy|7
2.16.840.1.113883.3.117.1.7.1.423|Statin Allergen|36
2.16.840.1.113883.3.117.1.7.1.424|Non-Elective Inpatient Encounter|2
2.16.840.1.113883.3.117.1.7.1.473|Medical Reason|19
2.16.840.1.113883.3.117.1.7.1.70|Birth|1
2.16.840.1.113883.3.117.1.7.1.75|Neonatal Intensive Care Unit (NICU)|1
2.16.840.1.113883.3.117.1.7.1.799|LDL-c Test|1
2.16.840.1.113883.3.117.1.7.1.82|Discharge To Home Or Police Custody|8
2.16.840.1.113883.3.117.1.7.1.87|Discharge To Another Hospital|2
2.16.840.1.113883.3.117.1.7.1.93|Patient Refusal|20
2.16.840.1.113883.3.1257.1.1504|BH Condition Involving Bipolar Disorder|174
2.16.840.1.113883.3.1257.1.1505|BH Condition Involving Unipolar Depression|76
2.16.840.1.113883.3.1257.1.1533|BH Electroconvulsive Therapy|15
2.16.840.1.113883.3.1257.1.1604|BH Assessment for Alcohol or Other Drugs|12
2.16.840.1.113883.3.1257.1.1616|BH Counseling for Depression|1
2.16.840.1.113883.3.1257.1.1652|BH Medical or psychiatric consultation|12
2.16.840.1.113883.3.1257.1.950|BH Mood Stabilizer Medication|39
2.16.840.1.113883.3.1257.1.972|BH Antidepressant Medication|195
2.16.840.1.113883.3.1257.1.973|BH Outpatient Psychotherapy|37
2.16.840.1.113883.3.464.1.49|BH Outpatient encounter|80
2.16.840.1.113883.3.464.1003.101.12.1001|Office Visit|9
2.16.840.1.113883.3.464.1003.101.12.1002|Hospital Observation Care - Initial|3
2.16.840.1.113883.3.464.1003.101.12.1004|Hospital Inpatient Visit - Initial|3
2.16.840.1.113883.3.464.1003.101.12.1006|Discharge Services - Hospital Inpatient Same Day Discharge|3
2.16.840.1.113883.3.464.1003.101.12.1007|Discharge Services - Hospital Inpatient|2
2.16.840.1.113883.3.464.1003.101.12.1008|Outpatient Consultation|5
2.16.840.1.113883.3.464.1003.101.12.1010|Emergency Department Visit|5
2.16.840.1.113883.3.464.1003.101.12.1012|Nursing Facility Visit|7
2.16.840.1.113883.3.464.1003.101.12.1013|Discharge Services - Nursing Facility|2
2.16.840.1.113883.3.464.1003.101.12.1014|Care Services in Long-Term Residential Facility|9
2.16.840.1.113883.3.464.1003.101.12.1016|Home Healthcare Services|9
2.16.840.1.113883.3.464.1003.101.12.1022|Preventive Care- Initial Office Visit, 0 to 17|4
2.16.840.1.113883.3.464.1003.101.12.1023|Preventive Care Services-Initial Office Visit, 18 and Up|3
2.16.840.1.113883.3.464.1003.101.12.1024|Preventive Care - Established Office Visit, 0 to 17|4
2.16.840.1.113883.3.464.1003.101.12.1025|Preventive Care Services - Established Office Visit, 18 and Up|3
2.16.840.1.113883.3.464.1003.101.12.1026|Preventive Care Services-Individual Counseling|4
2.16.840.1.113883.3.464.1003.101.12.1027|Preventive Care Services - Group Counseling|2
2.16.840.1.113883.3.464.1003.101.12.1030|Preventive Care Services - Other|2
2.16.840.1.113883.3.464.1003.101.12.1031|Telehealth Services|4
2.16.840.1.113883.3.464.1003.101.12.1039|Discharge Services- Observation Care|1
2.16.840.1.113883.3.464.1003.101.12.1046|Referral|181
2.16.840.1.113883.3.464.1003.101.12.1047|HIV Visit|43
2.16.840.1.113883.3.464.1003.101.12.1048|Face-to-Face Interaction|15
2.16.840.1.113883.3.464.1003.101.12.1053|Telephone Management|3
2.16.840.1.113883.3.464.1003.101.12.1054|Behavioral Health Follow-up Visit|10
2.16.840.1.113883.3.464.1003.101.12.1055|Psychotherapy and Pharmacologic Management|6
2.16.840.1.113883.3.464.1003.101.12.1056|Blood Pressure Visit|60
2.16.840.1.113883.3.464.1003.101.12.1059|Detoxification Visit|12
2.16.840.1.113883.3.464.1003.101.12.1060|Inpatient Encounter|74
2.16.840.1.113883.3.464.1003.101.12.1061|Ambulatory/ED Visit|46
2.16.840.1.113883.3.464.1003.102.12.1002|Cystic Fibrosis|16
2.16.840.1.113883.3.464.1003.102.12.1004|Emphysema|41
2.16.840.1.113883.3.464.1003.102.12.1007|Chronic Obstructive Pulmonary Disease|15
2.16.840.1.113883.3.464.1003.102.12.1011|Acute Pharyngitis|19
2.16.840.1.113883.3.464.1003.102.12.1012|Acute Tonsillitis|19
2.16.840.1.113883.3.464.1003.102.12.1017|Competing Conditions for Respiratory Conditions|3135
2.16.840.1.113883.3.464.1003.102.12.1018|Acute Respiratory Failure|10
2.16.840.1.113883.3.464.1003.102.12.1022|Upper Respiratory Infection|14
2.16.840.1.113883.3.464.1003.102.12.1023|Persistent Asthma|13
2.16.840.1.113883.3.464.1003.103.12.1001|Diabetes|171
2.16.840.1.113883.3.464.1003.103.12.1012|Diabetes Visit|91
2.16.840.1.113883.3.464.1003.103.12.1013|Visual Exam of Foot|1
2.16.840.1.113883.3.464.1003.103.12.1014|Sensory Exam of Foot|1
2.16.840.1.113883.3.464.1003.103.12.1015|Pulse Exam of Foot|1
2.16.840.1.113883.3.464.1003.104.12.1001|Acute Myocardial Infarction|60
2.16.840.1.113883.3.464.1003.104.12.1002|Coronary Artery Bypass Graft|67
2.16.840.1.113883.3.464.1003.104.12.1003|Ischemic Vascular Disease|560
2.16.840.1.113883.3.464.1003.104.12.1010|Percutaneous Coronary Interventions|27
2.16.840.1.113883.3.464.1003.104.12.1011|Essential Hypertension|16
2.16.840.1.113883.3.464.1003.104.12.1012|HDL-C Laboratory Test|1
2.16.840.1.113883.3.464.1003.104.12.1013|Total Cholesterol Laboratory Test|1
2.16.840.1.113883.3.464.1003.104.12.1014|Triglycerides Laboratory Test|2
2.16.840.1.113883.3.464.1003.104.12.1017|Valvular Heart Disease|745
2.16.840.1.113883.3.464.1003.104.12.1018|Computed Value INR percent TTR|1
2.16.840.1.113883.3.464.1003.105.12.1004|Mental Health Diagnoses|1426
2.16.840.1.113883.3.464.1003.105.12.1007|Major Depression|70
2.16.840.1.113883.3.464.1003.106.12.1001|Alcohol and Drug Dependence|767
2.16.840.1.113883.3.464.1003.106.12.1003|IV Drug Abuse|206
2.16.840.1.113883.3.464.1003.106.12.1004|Substance Abuse|439
2.16.840.1.113883.3.464.1003.106.12.1005|Alcohol and Drug Dependence Treatment|29
2.16.840.1.113883.3.464.1003.108.12.1001|Malignant Neoplasm of Colon|69
2.16.840.1.113883.3.464.1003.108.12.1009|Malignant Neoplasm of Lymphatic and Hematopietic Tissue|1012
2.16.840.1.113883.3.464.1003.108.12.1011|All Cancer|3288
2.16.840.1.113883.3.464.1003.108.12.1017|Pap Test|10
2.16.840.1.113883.3.464.1003.108.12.1018|Mammogram|87
2.16.840.1.113883.3.464.1003.108.12.1020|Colonoscopy|42
2.16.840.1.113883.3.464.1003.109.12.1004|Diabetic Nephropathy|29
2.16.840.1.113883.3.464.1003.109.12.1005|Microalbumin Test|52
2.16.840.1.113883.3.464.1003.109.12.1011|Vascular Access for Dialysis|52
2.16.840.1.113883.3.464.1003.109.12.1012|Kidney Transplant|14
2.16.840.1.113883.3.464.1003.109.12.1013|Dialysis Services|53
2.16.840.1.113883.3.464.1003.109.12.1014|ESRD Monthly Outpatient Services|15
2.16.840.1.113883.3.464.1003.109.12.1015|Other Services Related to Dialysis|7
2.16.840.1.113883.3.464.1003.109.12.1016|Dialysis Education|4
2.16.840.1.113883.3.464.1003.109.12.1017|Hypertensive Chronic Kidney Disease|54
2.16.840.1.113883.3.464.1003.109.12.1018|Glomerulonephritis and Nephrotic Syndrome|321
2.16.840.1.113883.3.464.1003.109.12.1019|Macroalbumin Test|10
2.16.840.1.113883.3.464.1003.110.12.1022|DTaP Vaccine Administered|12
2.16.840.1.113883.3.464.1003.110.12.1024|Hepatitis A|14
2.16.840.1.113883.3.464.1003.110.12.1025|Hepatitis B|40
2.16.840.1.113883.3.464.1003.110.12.1027|Pneumococcal Vaccine|1
2.16.840.1.113883.3.464.1003.110.12.1028|History of Pneumococcal Vaccine|2
2.16.840.1.113883.3.464.1003.110.12.1031|Measles, Mumps and Rubella (MMR) Vaccine Administered|5
2.16.840.1.113883.3.464.1003.110.12.1032|Mumps|40
2.16.840.1.113883.3.464.1003.110.12.1034|Pneumococcal Vaccine Administered|3
2.16.840.1.113883.3.464.1003.110.12.1037|Rubella|29
2.16.840.1.113883.3.464.1003.110.12.1039|Varicella Zoster|94
2.16.840.1.113883.3.464.1003.110.12.1040|Varicella Zoster Vaccine (VZV) Administered|5
2.16.840.1.113883.3.464.1003.110.12.1041|Hepatitis A Vaccine Administered|6
2.16.840.1.113883.3.464.1003.110.12.1042|Hepatitis B Vaccine Administered|18
2.16.840.1.113883.3.464.1003.110.12.1043|Hemophilus Influenze B (HiB) Vaccine Administered|15
2.16.840.1.113883.3.464.1003.110.12.1044|Influenza Vaccine Administered|5
2.16.840.1.113883.3.464.1003.110.12.1045|Inactivated Polio Vaccine (IPV) Administered|15
2.16.840.1.113883.3.464.1003.110.12.1046|Pneumococcal Conjugate Vaccine Administered|3
2.16.840.1.113883.3.464.1003.110.12.1047|Rotavirus Vaccine (3 dose schedule) Administered|1
2.16.840.1.113883.3.464.1003.110.12.1048|Rotavirus Vaccine (2 dose schedule) Administered|1
2.16.840.1.113883.3.464.1003.110.12.1049|Genital Herpes|22
2.16.840.1.113883.3.464.1003.110.12.1051|Lab Tests for Sexually Transmitted Infections|151
2.16.840.1.113883.3.464.1003.110.12.1052|Chlamydia Screening|56
2.16.840.1.113883.3.464.1003.110.12.1053|Measles|29
2.16.840.1.113883.3.464.1003.110.12.1054|Seropositive|1
2.16.840.1.113883.3.464.1003.111.12.1006|Other Female Reproductive Conditions|175
2.16.840.1.113883.3.464.1003.111.12.1007|Lab Tests During Pregnancy|30
2.16.840.1.113883.3.464.1003.111.12.1008|Diagnostic Studies During Pregnancy|599
2.16.840.1.113883.3.464.1003.111.12.1009|Procedures During Pregnancy|187
2.16.840.1.113883.3.464.1003.111.12.1010|Procedures Involving Contraceptive Devices|25
2.16.840.1.113883.3.464.1003.111.12.1011|Pregnancy Test|22
2.16.840.1.113883.3.464.1003.111.12.1012|Complications of Pregnancy, Childbirth and the Puerperium|3516
2.16.840.1.113883.3.464.1003.111.12.1013|Maternal Post Partum Depression Care|1
2.16.840.1.113883.3.464.1003.111.12.1014|Maternal Post Partum Depression Screening|1
2.16.840.1.113883.3.464.1003.111.12.1015|Delivery Live Births|113
2.16.840.1.113883.3.464.1003.112.12.1001|Gonococcal Infections and Venereal Diseases|213
2.16.840.1.113883.3.464.1003.112.12.1002|Syphilis|320
2.16.840.1.113883.3.464.1003.112.12.1003|Chlamydia|31
2.16.840.1.113883.3.464.1003.112.12.1004|Inflammatory Diseases of Female Reproductive Organs|306
2.16.840.1.113883.3.464.1003.113.12.1001|Low Back Pain|87
2.16.840.1.113883.3.464.1003.113.12.1033|X-Ray of Lower Spine|114
2.16.840.1.113883.3.464.1003.113.12.1034|MRI of Lower Spine|22
2.16.840.1.113883.3.464.1003.113.12.1035|CT Scan of Lower Spine|18
2.16.840.1.113883.3.464.1003.113.12.1036|Trauma|25006
2.16.840.1.113883.3.464.1003.113.12.1037|Fracture - Lower Body|5613
2.16.840.1.113883.3.464.1003.114.12.1007|Encephalopathy|17
2.16.840.1.113883.3.464.1003.114.12.1011|Narcolepsy|14
2.16.840.1.113883.3.464.1003.114.12.1012|Neurologic impairment|12
2.16.840.1.113883.3.464.1003.115.12.1088|Retinal or Dilated Eye Exam|22
2.16.840.1.113883.3.464.1003.118.12.1009|Patient not ambulatory|9
2.16.840.1.113883.3.464.1003.118.12.1028|Falls Screening|2
2.16.840.1.113883.3.464.1003.118.12.1029|Functional Status Assessment  for Hip Replacement|79
2.16.840.1.113883.3.464.1003.118.12.1030|Functional Status Assessment for Knee Replacement|79
2.16.840.1.113883.3.464.1003.118.12.1031|Functional Status Assessment for Heart Failure|85
2.16.840.1.113883.3.464.1003.118.12.1035|Counseling for Physical Activity|26
2.16.840.1.113883.3.464.1003.120.12.1001|Disorders of the Immune System|306
2.16.840.1.113883.3.464.1003.120.12.1002|HIV Viral Load|10
2.16.840.1.113883.3.464.1003.120.12.1003|HIV|40
2.16.840.1.113883.3.464.1003.121.12.1004|CD4+ Count|5
2.16.840.1.113883.3.464.1003.121.12.1005|CD4+ Percentage|7
2.16.840.1.113883.3.464.1003.121.12.1006|Consultant Report|3
2.16.840.1.113883.3.464.1003.121.12.1012|BMI percentile|3
2.16.840.1.113883.3.464.1003.121.12.1013|Delta systolic blood pressure|1
2.16.840.1.113883.3.464.1003.121.12.1014|Height|6
2.16.840.1.113883.3.464.1003.121.12.1015|Weight|7
2.16.840.1.113883.3.464.1003.121.12.1016|Positive Finding|1
2.16.840.1.113883.3.464.1003.122.12.1003|Ambulatory|2
2.16.840.1.113883.3.464.1003.125.12.1002|Fluoride Varnish Application for Children|6
2.16.840.1.113883.3.464.1003.125.12.1003|Clinical Oral Evaluation|7
2.16.840.1.113883.3.464.1003.125.12.1004|Dental Caries|56
2.16.840.1.113883.3.464.1003.195.12.1002|Negative Finding|1
2.16.840.1.113883.3.464.1003.195.12.1003|Counseling for Nutrition|49
2.16.840.1.113883.3.464.1003.196.12.1001|Antibiotic Medications for Pharyngitis|304
2.16.840.1.113883.3.464.1003.196.12.1076|Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis|12
2.16.840.1.113883.3.464.1003.196.12.1080|Contraceptive Medications|131
2.16.840.1.113883.3.464.1003.196.12.1143|Isotretinoin|4
2.16.840.1.113883.3.464.1003.196.12.1170|Varicella Zoster Vaccine (VZV)|2
2.16.840.1.113883.3.464.1003.196.12.1171|ADHD Medications|81
2.16.840.1.113883.3.464.1003.196.12.1202|Dapsone and pyrimethamine|1
2.16.840.1.113883.3.464.1003.196.12.1205|Leucovorin|7
2.16.840.1.113883.3.464.1003.196.12.1211|Aspirin and Other Anti-thrombotics|28
2.16.840.1.113883.3.464.1003.196.12.1212|Preferred Asthma Therapy|157
2.16.840.1.113883.3.464.1003.196.12.1213|Antidepressant Medication|166
2.16.840.1.113883.3.464.1003.196.12.1214|DTaP Vaccine|6
2.16.840.1.113883.3.464.1003.196.12.1215|Hepatitis A Vaccine|2
2.16.840.1.113883.3.464.1003.196.12.1216|Hepatitis B Vaccine|5
2.16.840.1.113883.3.464.1003.196.12.1217|Hemophilus Influenze B (HiB) Vaccine|5
2.16.840.1.113883.3.464.1003.196.12.1218|Influenza Vaccine|2
2.16.840.1.113883.3.464.1003.196.12.1219|Inactivated Polio Vaccine (IPV)|3
2.16.840.1.113883.3.464.1003.196.12.1221|Pneumococcal Conjugate Vaccine|3
2.16.840.1.113883.3.464.1003.196.12.1222|Rotavirus Vaccine (2 dose schedule)|1
2.16.840.1.113883.3.464.1003.196.12.1223|Rotavirus Vaccine (3 dose schedule)|1
2.16.840.1.113883.3.464.1003.196.12.1224|Measles, Mumps and Rubella (MMR) Vaccine|2
2.16.840.1.113883.3.464.1003.196.12.1253|High Risk Medications for the Elderly|786
2.16.840.1.113883.3.464.1003.196.12.1254|High-Risk Medications With Days Supply Criteria|18
2.16.840.1.113883.3.464.1003.198.12.1005|Bilateral Mastectomy|8
2.16.840.1.113883.3.464.1003.198.12.1006|Primary THA Procedure|23
2.16.840.1.113883.3.464.1003.198.12.1007|Primary TKA Procedure|11
2.16.840.1.113883.3.464.1003.198.12.1010|Flexible Sigmoidoscopy|18
2.16.840.1.113883.3.464.1003.198.12.1011|Fecal Occult Blood Test (FOBT)|15
2.16.840.1.113883.3.464.1003.198.12.1012|Group A Streptococcus Test|13
2.16.840.1.113883.3.464.1003.198.12.1013|HbA1c Laboratory Test|3
2.16.840.1.113883.3.464.1003.198.12.1014|Hysterectomy with No Residual Cervix|77
2.16.840.1.113883.3.464.1003.198.12.1019|Total Colectomy|23
2.16.840.1.113883.3.464.1003.198.12.1020|Unilateral Mastectomy|38
2.16.840.1.113883.3.464.1003.198.12.1028|Mumps Antigen Test|19
2.16.840.1.113883.3.464.1003.198.12.1029|Measles Antigen Test|13
2.16.840.1.113883.3.464.1003.198.12.1030|Rubella Antigen Test|9
2.16.840.1.113883.3.464.1003.198.12.1031|Hepatitis B Antigen Test|2
2.16.840.1.113883.3.464.1003.198.12.1032|Varicella Zoster Antigen Test|15
2.16.840.1.113883.3.464.1003.198.12.1033|Hepatitis A Antigen Test|6
2.16.840.1.113883.3.464.1003.198.12.1034|X-Ray Study (all inclusive)|2727
2.16.840.1.113883.3.464.1003.199.12.1021|Anaphylactic Reaction to Rotavirus Vaccine|1
2.16.840.1.113883.3.464.1003.199.12.1022|Anaphylactic Reaction to Influenza Vaccine|1
2.16.840.1.113883.3.464.1003.199.12.1023|Anaphylactic Reaction to Inactivated Polio Vaccine (IPV)|1
2.16.840.1.113883.3.464.1003.199.12.1024|Anaphylactic Reaction to Neomycin|1
2.16.840.1.113883.3.464.1003.199.12.1025|Anaphylactic Reaction to Polymyxin|1
2.16.840.1.113883.3.464.1003.199.12.1026|Anaphylactic Reaction to Hepatitis A Vaccine|1
2.16.840.1.113883.3.464.1003.199.12.1027|Anaphylactic Reaction to Pneumococcal Conjugate Vaccine|1
2.16.840.1.113883.3.464.1003.199.12.1028|Anaphylactic Reaction to Streptomycin|1
2.16.840.1.113883.3.464.1003.199.12.1029|Anaphylactic Reaction to Hepatitis B Vaccine|1
2.16.840.1.113883.3.464.1003.199.12.1030|Anaphylactic Reaction to Hemophilus Influenza B (HiB) Vaccine|1
2.16.840.1.113883.3.464.1003.199.12.1031|Anaphylactic Reaction to DTaP Vaccine|4
2.16.840.1.113883.3.464.1003.199.12.1032|Anaphylactic Reaction to Common Baker's Yeast|2
2.16.840.1.113883.3.526.2.1044|Systolic Blood Pressure|1
2.16.840.1.113883.3.526.2.1045|Diastolic Blood Pressure|1
2.16.840.1.113883.3.526.2.643|Clinical Trial Participant|1
2.16.840.1.113883.3.526.3.1002|Chronic Kidney Disease, Stage 5|3
2.16.840.1.113883.3.526.3.1003|Proteinuria|12
2.16.840.1.113883.3.526.3.1005|Dementia & Mental Degenerations|96
2.16.840.1.113883.3.526.3.1006|Standardized Tools for Assessment of Cognition|7
2.16.840.1.113883.3.526.3.1007|Medical Reason|22
2.16.840.1.113883.3.526.3.1008|Patient Reason|35
2.16.840.1.113883.3.526.3.1009|System Reason|14
2.16.840.1.113883.3.526.3.1010|Cancer|5936
2.16.840.1.113883.3.526.3.1011|Occupational Therapy Evaluation|2
2.16.840.1.113883.3.526.3.1012|Patient Provider Interaction|31
2.16.840.1.113883.3.526.3.1018|Psych Visit - Family Psychotherapy|2
2.16.840.1.113883.3.526.3.1020|Health & Behavioral Assessment - Individual|1
2.16.840.1.113883.3.526.3.1023|Behavioral/Neuropsych Assessment|4
2.16.840.1.113883.3.526.3.1024|Palliative Care|2
2.16.840.1.113883.3.526.3.1025|Severe Dementia|1
2.16.840.1.113883.3.526.3.1026|Radiation Treatment Management|6
2.16.840.1.113883.3.526.3.1027|Chemotherapy Administration|42
2.16.840.1.113883.3.526.3.1028|Standardized Pain Assessment Tool|4
2.16.840.1.113883.3.526.3.1032|Systolic Blood Pressure|1
2.16.840.1.113883.3.526.3.1033|Diastolic Blood Pressure|1
2.16.840.1.113883.3.526.3.1083|Hemodialysis|22
2.16.840.1.113883.3.526.3.1084|Peritoneal Dialysis|32
2.16.840.1.113883.3.526.3.1090|Moderate or Severe LVSD|2
2.16.840.1.113883.3.526.3.1091|Left Ventricular Systolic Dysfunction|1
2.16.840.1.113883.3.526.3.1092|Moderate or Severe|2
2.16.840.1.113883.3.526.3.1098|Clinical Staging Procedure|1
2.16.840.1.113883.3.526.3.1125|Clinical Trial Participant|6
2.16.840.1.113883.3.526.3.1134|Ejection Fraction|15
2.16.840.1.113883.3.526.3.1139|ACE Inhibitor or ARB|151
2.16.840.1.113883.3.526.3.1140|Patient Reason for ACE Inhibitor or ARB Decline|2
2.16.840.1.113883.3.526.3.1141|Psychoanalysis|1
2.16.840.1.113883.3.526.3.1151|Renal Failure Due to ACE Inhibitor|2
2.16.840.1.113883.3.526.3.1164|Breast Cancer Primary Tumor Size T1a|1
2.16.840.1.113883.3.526.3.1170|Tobacco User|28
2.16.840.1.113883.3.526.3.1174|Beta Blocker Therapy|80
2.16.840.1.113883.3.526.3.1176|Heart Rate|1
2.16.840.1.113883.3.526.3.1177|Allergy to Beta Blocker Therapy|24
2.16.840.1.113883.3.526.3.1178|Intolerance to Beta Blocker Therapy|23
2.16.840.1.113883.3.526.3.1184|Beta Blocker Therapy for LVSD|20
2.16.840.1.113883.3.526.3.1185|Previous Receipt of Influenza Vaccine|4
2.16.840.1.113883.3.526.3.1187|Group Psychotherapy|1
2.16.840.1.113883.3.526.3.1189|Tobacco Non-User|27
2.16.840.1.113883.3.526.3.1190|Tobacco Use Cessation Pharmacotherapy|41
2.16.840.1.113883.3.526.3.1193|Cardiac Pacer|5
2.16.840.1.113883.3.526.3.1197|Breast Cancer Primary Tumor Size T1mi|1
2.16.840.1.113883.3.526.3.1211|Allergy to ACE Inhibitor or ARB|14
2.16.840.1.113883.3.526.3.1212|Intolerance to ACE Inhibitor or ARB|16
2.16.840.1.113883.3.526.3.1240|Annual Wellness Visit|2
2.16.840.1.113883.3.526.3.1241|Acute and Subacute Iridocyclitis|48
2.16.840.1.113883.3.526.3.1245|Health and Behavioral Assessment - Initial|1
2.16.840.1.113883.3.526.3.1248|LDL-C Laboratory Test|3
2.16.840.1.113883.3.526.3.1251|Macular Exam|1
2.16.840.1.113883.3.526.3.1252|Encounter-Influenza|80
2.16.840.1.113883.3.526.3.1253|Allergy to Eggs|2
2.16.840.1.113883.3.526.3.1254|Influenza Vaccine|7
2.16.840.1.113883.3.526.3.1255|Influenza Vaccination Declined|1
2.16.840.1.113883.3.526.3.1256|Allergy to Influenza Vaccine|4
2.16.840.1.113883.3.526.3.1257|Intolerance to Influenza Vaccine|4
2.16.840.1.113883.3.526.3.1259|Limited Life Expectancy|5
2.16.840.1.113883.3.526.3.1270|Breast Cancer Primary Tumor Size T1b|1
2.16.840.1.113883.3.526.3.1278|Tobacco Use Screening|3
2.16.840.1.113883.3.526.3.1279|ECOG Performance Status-Poor|3
2.16.840.1.113883.3.526.3.1280|Allergy to Antineoplastic Therapy|2
2.16.840.1.113883.3.526.3.1283|Level of Severity of Retinopathy Findings|5
2.16.840.1.113883.3.526.3.1284|Macular Edema Findings Absent|1
2.16.840.1.113883.3.526.3.1285|Ophthalmological Services|4
2.16.840.1.113883.3.526.3.1287|Intolerance to Antineoplastic Therapy|2
2.16.840.1.113883.3.526.3.1288|Chemotherapy for Colon Cancer - Capecitabine|2
2.16.840.1.113883.3.526.3.1289|Chemotherapy for Colon Cancer - Fluorouracil|1
2.16.840.1.113883.3.526.3.1290|Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin|8
2.16.840.1.113883.3.526.3.1291|Chemotherapy for Colon Cancer - Oxaliplatin|1
2.16.840.1.113883.3.526.3.1292|Colon Cancer Primary Tumor Size T1|1
2.16.840.1.113883.3.526.3.1293|Colon Cancer Primary Tumor Size T2|1
2.16.840.1.113883.3.526.3.1294|Colon Cancer Primary Tumor Size T3|1
2.16.840.1.113883.3.526.3.1295|Colon Cancer Primary Tumor Size T4a|1
2.16.840.1.113883.3.526.3.1296|Colon Cancer Primary Tumor Size T4b|1
2.16.840.1.113883.3.526.3.1297|Colon Cancer Regional Lymph Node Status N1|1
2.16.840.1.113883.3.526.3.1298|Colon Cancer Regional Lymph Node Status N1c|1
2.16.840.1.113883.3.526.3.1299|Colon Cancer Regional Lymph Node Status N2|1
2.16.840.1.113883.3.526.3.1300|Colon Cancer Regional Lymph Node Status N2a|1
2.16.840.1.113883.3.526.3.1301|Colon Cancer Regional Lymph Node Status N2b|1
2.16.840.1.113883.3.526.3.1302|Breast Distant Metastasis Status M0|1
2.16.840.1.113883.3.526.3.1303|Breast Cancer ER or PR Positive|4
2.16.840.1.113883.3.526.3.1304|Breast Cancer Primary Tumor Size T0|1
2.16.840.1.113883.3.526.3.1305|Breast Cancer Primary Tumor Size T1|1
2.16.840.1.113883.3.526.3.1306|Breast Cancer Primary Tumor Size T1c|1
2.16.840.1.113883.3.526.3.1307|Breast Cancer Primary Tumor Size T2|1
2.16.840.1.113883.3.526.3.1308|Breast Cancer Primary Tumor Size T3|1
2.16.840.1.113883.3.526.3.1309|Breast Cancer Primary Tumor Size T4|1
2.16.840.1.113883.3.526.3.1310|Breast Cancer Regional Lymph Node Status N0|1
2.16.840.1.113883.3.526.3.1311|Breast Cancer Regional Lymph Node Status pN1a|1
2.16.840.1.113883.3.526.3.1312|Breast Cancer Regional Lymph Node Status pN1mi|1
2.16.840.1.113883.3.526.3.1313|Breast Cancer Regional Lymph Node Status N2|1
2.16.840.1.113883.3.526.3.1314|Breast Cancer Regional Lymph Node Status N3|1
2.16.840.1.113883.3.526.3.1315|Tamoxifen or Aromatase Inhibitor Therapy|8
2.16.840.1.113883.3.526.3.1316|Gonadotropin-Releasing Hormone Analogue Medication|27
2.16.840.1.113883.3.526.3.1317|Allergy to Tamoxifen or Aromatase Inhibitor Therapy|1
2.16.840.1.113883.3.526.3.1318|Intolerance to Tamoxifen or Aromatase Inhibitor Therapy|2
2.16.840.1.113883.3.526.3.1320|Macular Edema Findings Present|17
2.16.840.1.113883.3.526.3.1325|Prostate Cancer Primary Tumor Size T1c|1
2.16.840.1.113883.3.526.3.1326|Prostate Cancer Primary Tumor Size T2a|1
2.16.840.1.113883.3.526.3.1327|Colon Cancer Regional Lymph Node Status N1a|1
2.16.840.1.113883.3.526.3.1328|Colon Cancer Regional Lymph Node Status N1b|1
2.16.840.1.113883.3.526.3.1329|Breast Cancer Regional Lymph Node Status N1|1
2.16.840.1.113883.3.526.3.1330|Breast Cancer Regional Lymph Node Status pN1b|1
2.16.840.1.113883.3.526.3.1331|Breast Cancer Regional Lymph Node Status pN1c|1
2.16.840.1.113883.3.526.3.1332|Cognitive Assessment|2
2.16.840.1.113883.3.526.3.1333|Cup to Disc Ratio|2
2.16.840.1.113883.3.526.3.1334|Optic Disc Exam for Structural Abnormalities|2
2.16.840.1.113883.3.526.3.1337|Colon Distant Metastasis Status M0|1
2.16.840.1.113883.3.526.3.1339|Radiation Therapy II|56
2.16.840.1.113883.3.526.3.1405|Adhesions and Disruptions of Iris and Ciliary Body|79
2.16.840.1.113883.3.526.3.1406|Anomalies of Puillary Function|7
2.16.840.1.113883.3.526.3.1407|Aphakia and Other Disorders of Lens|24
2.16.840.1.113883.3.526.3.1408|Aspiration and Injection Procedures|6
2.16.840.1.113883.3.526.3.1409|Burn Confined to Eye and Adnexa|91
2.16.840.1.113883.3.526.3.1410|Cataract Secondary to Ocular Disorders|16
2.16.840.1.113883.3.526.3.1411|Cataract Surgery|54
2.16.840.1.113883.3.526.3.1412|Cataract, Congenital|19
2.16.840.1.113883.3.526.3.1413|Cataract, Mature or Hypermature|8
2.16.840.1.113883.3.526.3.1414|Cataract, Posterior Polar|10
2.16.840.1.113883.3.526.3.1415|Certain Types of Iridocyclitis|36
2.16.840.1.113883.3.526.3.1416|Chronic Iridocyclitis|11
2.16.840.1.113883.3.526.3.1417|Cloudy Cornea|31
2.16.840.1.113883.3.526.3.1418|Corneal Edema|34
2.16.840.1.113883.3.526.3.1419|Corneal Opacity and Other Disorders of Cornea|30
2.16.840.1.113883.3.526.3.1420|Cysts of Iris, Ciliary Body, and Anterior Chamber|30
2.16.840.1.113883.3.526.3.1421|Enophthalmos|20
2.16.840.1.113883.3.526.3.1422|Excision of Adhesions|4
2.16.840.1.113883.3.526.3.1423|Glaucoma|264
2.16.840.1.113883.3.526.3.1424|Hereditary Corneal Dystrophies|53
2.16.840.1.113883.3.526.3.1425|High Hyperopia|13
2.16.840.1.113883.3.526.3.1426|Hypotony of Eye|31
2.16.840.1.113883.3.526.3.1427|Injury to Optic Nerve and Pathways|23
2.16.840.1.113883.3.526.3.1428|Central Corneal Ulcer|12
2.16.840.1.113883.3.526.3.1429|Lens Procedure|14
2.16.840.1.113883.3.526.3.1430|Open Wound of Eyeball|61
2.16.840.1.113883.3.526.3.1432|Pathologic Myopia|18
2.16.840.1.113883.3.526.3.1433|Posterior Lenticonus|12
2.16.840.1.113883.3.526.3.1434|Prior Pars Plana Vitrectomy|7
2.16.840.1.113883.3.526.3.1435|Pseudoexfoliation Syndrome|22
2.16.840.1.113883.3.526.3.1436|Removal Procedures|60
2.16.840.1.113883.3.526.3.1437|Retinal Repair Procedures|23
2.16.840.1.113883.3.526.3.1438|Retrolental Fibroplasias|11
2.16.840.1.113883.3.526.3.1439|Revision Procedures|4
2.16.840.1.113883.3.526.3.1440|Scleral Procedures|4
2.16.840.1.113883.3.526.3.1441|Senile Cataract|11
2.16.840.1.113883.3.526.3.1442|Use of Systemic Sympathetic alpha-1a Antagonist Medication for Treatment of Prostatic Hypertrophy|23
2.16.840.1.113883.3.526.3.1443|Traumatic Cataract|25
2.16.840.1.113883.3.526.3.1444|Uveitis|41
2.16.840.1.113883.3.526.3.1445|Vascular Disorders of Iris and Ciliary Body|7
2.16.840.1.113883.3.526.3.1446|Visual Field Defects|47
2.16.840.1.113883.3.526.3.1447|Vitreous Procedures|16
2.16.840.1.113883.3.526.3.1448|Amblyopia|28
2.16.840.1.113883.3.526.3.1449|Chorioretinal Scars|33
2.16.840.1.113883.3.526.3.1450|Choroidal Degenerations|18
2.16.840.1.113883.3.526.3.1451|Choroidal Detachment|11
2.16.840.1.113883.3.526.3.1452|Choroidal Hemorrhage and Rupture|19
2.16.840.1.113883.3.526.3.1453|Degeneration of Macula and Posterior Pole|103
2.16.840.1.113883.3.526.3.1454|Degenerative Disorders of Globe|58
2.16.840.1.113883.3.526.3.1455|Diabetic Macular Edema|28
2.16.840.1.113883.3.526.3.1457|Disorders of Optic Chiasm|23
2.16.840.1.113883.3.526.3.1458|Disorders of Visual Cortex|14
2.16.840.1.113883.3.526.3.1459|Disseminated Chorioretinitis and Disseminated Retinochoroiditis|38
2.16.840.1.113883.3.526.3.1460|Focal Chorioretinitis and Focal Retinochoroiditis|39
2.16.840.1.113883.3.526.3.1461|Glaucoma Associated with Congenital Anomalies, Dystrophies, and Systemic Syndromes|115
2.16.840.1.113883.3.526.3.1462|Hereditary Choroidal Dystrophies|21
2.16.840.1.113883.3.526.3.1463|Hereditary Retinal Dystrophies|32
2.16.840.1.113883.3.526.3.1464|Moderate or Severe Impairment, Better Eye, Profound Impairment Lesser Eye|18
2.16.840.1.113883.3.526.3.1465|Nystagmus and Other Irregular Eye Movements|6
2.16.840.1.113883.3.526.3.1466|Optic Atrophy|42
2.16.840.1.113883.3.526.3.1467|Optic Neuritis|36
2.16.840.1.113883.3.526.3.1468|Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis|81
2.16.840.1.113883.3.526.3.1469|Other Background Retinopathy and Retinal Vascular Changes|32
2.16.840.1.113883.3.526.3.1470|Other Corneal Deformities|28
2.16.840.1.113883.3.526.3.1471|Other Disorders of Optic Nerve|10
2.16.840.1.113883.3.526.3.1472|Other Disorders of Sclera|12
2.16.840.1.113883.3.526.3.1473|Other Endophthalmitis|35
2.16.840.1.113883.3.526.3.1474|Other Retinal Disorders|39
2.16.840.1.113883.3.526.3.1475|Prior Penetrating Keratoplasty|22
2.16.840.1.113883.3.526.3.1476|Profound Impairment, Both Eyes|41
2.16.840.1.113883.3.526.3.1477|Purulent Endophthalmitis|40
2.16.840.1.113883.3.526.3.1478|Retinal Detachment with Retinal Defect|59
2.16.840.1.113883.3.526.3.1479|Retinal Vascular Occlusion|44
2.16.840.1.113883.3.526.3.1480|Other Proliferative Retinopathy|46
2.16.840.1.113883.3.526.3.1481|Scleritis and Episcleritis|52
2.16.840.1.113883.3.526.3.1482|Separation of Retinal Layers|54
2.16.840.1.113883.3.526.3.1483|Visual Acuity 20/40 or Better|4
2.16.840.1.113883.3.526.3.1484|Suicide Risk Assessment|1
2.16.840.1.113883.3.526.3.1485|Chemotherapy for Colon Cancer - Capecitabine Ingredient|2
2.16.840.1.113883.3.526.3.1486|Chemotherapy for Colon Cancer - Fluorouracil Ingredient|5
2.16.840.1.113883.3.526.3.1487|Tamoxifen or Aromatase Inhibitor Therapy Ingredient|10
2.16.840.1.113883.3.526.3.1488|Best Corrected Visual Acuity|1
2.16.840.1.113883.3.526.3.1489|ACE Inhibitor or ARB Ingredient|87
2.16.840.1.113883.3.526.3.1490|Chemotherapy for Colon Cancer - Leucovorin and Levo-Leucovorin Ingredient|5
2.16.840.1.113883.3.526.3.1491|Major Depressive Disorder-Active|56
2.16.840.1.113883.3.526.3.1492|Psych Visit - Diagnostic Evaluation|2
2.16.840.1.113883.3.526.3.1493|Beta Blocker Therapy Ingredient|50
2.16.840.1.113883.3.526.3.1494|Reason Documented|1
2.16.840.1.113883.3.526.3.1495|Chemotherapy for Colon Cancer - Oxaliplatin Ingredient|2
2.16.840.1.113883.3.526.3.1496|Psych Visit - Psychotherapy|3
2.16.840.1.113883.3.526.3.319|Prostate Cancer|14
2.16.840.1.113883.3.526.3.320|Bone Scan|28
2.16.840.1.113883.3.526.3.326|Primary Open-Angle Glaucoma|44
2.16.840.1.113883.3.526.3.327|Diabetic Retinopathy|98
2.16.840.1.113883.3.526.3.353|End Stage Renal Disease|6
2.16.840.1.113883.3.526.3.362|Asthma|81
2.16.840.1.113883.3.526.3.366|Arrhythmia|89
2.16.840.1.113883.3.526.3.367|Atrioventricular Block|14
2.16.840.1.113883.3.526.3.368|Cardiac Pacer in Situ|3
2.16.840.1.113883.3.526.3.369|Coronary Artery Disease No MI|127
2.16.840.1.113883.3.526.3.370|Hypotension|30
2.16.840.1.113883.3.526.3.371|Cardiac Surgery|81
2.16.840.1.113883.3.526.3.376|Heart Failure|91
2.16.840.1.113883.3.526.3.378|Pregnancy|2241
2.16.840.1.113883.3.526.3.389|Breast Cancer|84
2.16.840.1.113883.3.526.3.391|Colon Cancer|44
2.16.840.1.113883.3.526.3.397|Gleason Score|1
2.16.840.1.113883.3.526.3.398|Prostate Cancer Treatment|108
2.16.840.1.113883.3.526.3.399|Salvage Therapy|8
2.16.840.1.113883.3.526.3.401|Prostate Specific Antigen Test|12
2.16.840.1.113883.3.526.3.402|Influenza Vaccination|19
2.16.840.1.113883.3.526.3.403|Myocardial Infarction|91
2.16.840.1.113883.3.526.3.412|Bradycardia|11
2.16.840.1.113883.3.526.3.447|Metastatic Sites Common to Breast Cancer|123
2.16.840.1.113883.3.526.3.451|Pain Related to Prostate Cancer|50
2.16.840.1.113883.3.526.3.471|Bilateral Oophorectomy|14
2.16.840.1.113883.3.526.3.485|Chemotherapy|37
2.16.840.1.113883.3.526.3.490|Metastatic Sites Common to Colon Cancer|13
2.16.840.1.113883.3.526.3.509|Tobacco Use Cessation Counseling|13
2.16.840.1.113883.3.560.100.1|Male|1
2.16.840.1.113883.3.560.100.2|Female|1
2.16.840.1.113883.3.560.100.4|birth date|1
2.16.840.1.113883.3.600.1.1498|Above Normal Medications|2
2.16.840.1.113883.3.600.1.1499|Below Normal Medications|5
2.16.840.1.113883.3.600.1.1502|Medical or Other reason not done|3
2.16.840.1.113883.3.600.1.1503|Patient Reason Refused|6
2.16.840.1.113883.3.600.1.1525|Above Normal Follow-up|38
2.16.840.1.113883.3.600.1.1527|Referrals where weight assessment may occur|31
2.16.840.1.113883.3.600.1.1528|Below Normal Follow up|13
2.16.840.1.113883.3.600.1.1579|Palliative Care|7
2.16.840.1.113883.3.600.1.1623|Pregnancy Dx|1983
2.16.840.1.113883.3.600.1.1751|BMI Encounter Code Set|70
2.16.840.1.113883.3.600.1.1834|Medications Encounter Code Set|148
2.16.840.1.113883.3.600.1.462|Current Medications Documented SNMD|1
2.16.840.1.113883.3.600.1.681|BMI LOINC Value|1
2.16.840.1.113883.3.600.145|Depression diagnosis|97
2.16.840.1.113883.3.600.1474|Followup within one year|14
2.16.840.1.113883.3.600.1475|Referral to Alternative Provider / Primary Care Provider|7
2.16.840.1.113883.3.600.1476|Anti-Hypertensive Pharmacologic Therapy|483
2.16.840.1.113883.3.600.1482|Laboratory Tests for Hypertension|9
2.16.840.1.113883.3.600.1508|Lifestyle Recommendation|3
2.16.840.1.113883.3.600.1510|Weight Reduction Recommended|6
2.16.840.1.113883.3.600.1515|Dietary Recommendations|32
2.16.840.1.113883.3.600.1518|Physical Activity Recommendation|10
2.16.840.1.113883.3.600.1521|Medical reason|3
2.16.840.1.113883.3.600.1537|Followup within 4 weeks|7
2.16.840.1.113883.3.600.1542|Additional evaluation for depression - adolescent|9
2.16.840.1.113883.3.600.1545|Additional evaluation for depression - adult|9
2.16.840.1.113883.3.600.1557|Family History CHD|1
2.16.840.1.113883.3.600.1561|Framingham coronary heart disease 10 year risk|1
2.16.840.1.113883.3.600.1622|Pregnancy|1964
2.16.840.1.113883.3.600.1916|Depression Screening Denominator Encounter Codes New|68
2.16.840.1.113883.3.600.1920|BP Screening Denominator Encounter Codes Grouped New|102
2.16.840.1.113883.3.600.1951|Cholesterol Measure Encounter Codes|79
2.16.840.1.113883.3.600.2387|Overweight|1
2.16.840.1.113883.3.600.2388|Underweight|1
2.16.840.1.113883.3.600.2390|Current Cigarette Smoker|22
2.16.840.1.113883.3.600.2395|Finding of Hypertension|8
2.16.840.1.113883.3.600.2448|ECG 12 lead or study order|2
2.16.840.1.113883.3.600.2449|Adult Depression Screening|1
2.16.840.1.113883.3.600.2450|Positive Depression Screening|1
2.16.840.1.113883.3.600.2451|Negative Depression Screening|1
2.16.840.1.113883.3.600.2452|Adolescent Depression Screening|1
2.16.840.1.113883.3.600.2454|Depression Screening Result|2
2.16.840.1.113883.3.600.263|Diagnosis of hypertension grouped|113
2.16.840.1.113883.3.600.450|Bipolar Diagnosis|113
2.16.840.1.113883.3.600.467|Follow-up for depression - adolescent|27
2.16.840.1.113883.3.600.468|Follow-up for depression - adult|27
2.16.840.1.113883.3.600.469|Depression medications - adolescent|9
2.16.840.1.113883.3.600.470|Depression medications - adult|216
2.16.840.1.113883.3.600.537|Referral for Depression Adolescent|19
2.16.840.1.113883.3.600.538|Referral for Depression Adult|21
2.16.840.1.113883.3.600.559|Suicide Risk Assessment|1
2.16.840.1.113883.3.600.791|Patient Reason refused|6
2.16.840.1.113883.3.600.792|Medical reason contraindicated|3
2.16.840.1.113883.3.600.823|Moderation of ETOH Consumption Recommendation|7
2.16.840.1.113883.3.600.863|CHD or CHD Risk Equivalent|371
2.16.840.1.113883.3.600.872|LDL Code|9
2.16.840.1.113883.3.600.875|High Density Lipoprotein (HDL)|3
2.16.840.1.113883.3.600.879|Total Cholesterol|2
2.16.840.1.113883.3.600.883|Triglycerides|4
2.16.840.1.113883.3.666.5.1058|Hospital Measures-Beta lactams for allergy determination|46
2.16.840.1.113883.3.666.5.1108|Hospital measures-Route IV|7
2.16.840.1.113883.3.666.5.1109|Hospital Measures-Route IV/IM|8
2.16.840.1.113883.3.666.5.1111|Hospital measures-Route IV, oral or IM|19
2.16.840.1.113883.3.666.5.1112|Hospital Measures-Route IV or PO|18
2.16.840.1.113883.3.666.5.1145|Hospital Measures - Hold|1
2.16.840.1.113883.3.666.5.1151|Hospital Measures-Aortic balloon pump insertion|4
2.16.840.1.113883.3.666.5.1566|Impaired Fetal Growth Group|66
2.16.840.1.113883.3.666.5.1567|Birth Trauma or Injuries Group|188
2.16.840.1.113883.3.666.5.1568|Newborn Affected by Placenta or Abruption Group|25
2.16.840.1.113883.3.666.5.1570|Congenital Anomalies Group|1579
2.16.840.1.113883.3.666.5.1571|Hemolytic Disease Group|20
2.16.840.1.113883.3.666.5.1573|Hydrops Group|10
2.16.840.1.113883.3.666.5.1574|Drug Withdrawal Syndrome Group|6
2.16.840.1.113883.3.666.5.1576|Laryngeal Stenosis Group|7
2.16.840.1.113883.3.666.5.1577|Hypoxia or Asphyxia Group|32
2.16.840.1.113883.3.666.5.1580|Congenital or Infantile Cerebral Palsy Group|29
2.16.840.1.113883.3.666.5.1581|Shock and Complications Group|50
2.16.840.1.113883.3.666.5.1582|Arterial or Umbilical Venous Cath Group|17
2.16.840.1.113883.3.666.5.1583|TPN Procedure Group|7
2.16.840.1.113883.3.666.5.1584|Gastrostomy Group|25
2.16.840.1.113883.3.666.5.1585|Gavage Feeding Group|4
2.16.840.1.113883.3.666.5.1586|Cardiopulmonary Resuscitation Group|3
2.16.840.1.113883.3.666.5.1588|Respiratory Problems Group|72
2.16.840.1.113883.3.666.5.1589|Respiratory Procedures Group|124
2.16.840.1.113883.3.666.5.1590|Infection Group|55
2.16.840.1.113883.3.666.5.1591|Neurologic Complications Group|79
2.16.840.1.113883.3.666.5.1592|Neurologic Procedure Group|56
2.16.840.1.113883.3.666.5.1593|Hyperbilirubinemia Group|4
2.16.840.1.113883.3.666.5.1594|Phototherapy Procedure Group|5
2.16.840.1.113883.3.666.5.1595|Social Reasons Group|121
2.16.840.1.113883.3.666.5.1596|Gestational age >= 37 weeks|8
2.16.840.1.113883.3.666.5.1618|Neonatal Death SM-CT|1
2.16.840.1.113883.3.666.5.1726|Hospital Measures-Immunodeficient Conditions|200
2.16.840.1.113883.3.666.5.1741|Hospital measures-Pacemaker or implantable defibrillator insertion procedure|142
2.16.840.1.113883.3.666.5.1743|General or Neuraxial Anesthesia|53
2.16.840.1.113883.3.666.5.1816|Hospital measures-Knee arthroplasty|44
2.16.840.1.113883.3.666.5.1921|Hospital Measures-Caesarean Section|20
2.16.840.1.113883.3.666.5.1940|Hospital Measures-Immunocompromised Conditions|852
2.16.840.1.113883.3.666.5.2128|IV Positive Inotropic and Vasopressor Agents|78
2.16.840.1.113883.3.666.5.2129|Paralytic Agents|22
2.16.840.1.113883.3.666.5.2160|Hospital Measures-Restrictive lung disease|5
2.16.840.1.113883.3.666.5.2162|Hospital Measures-Respiratory infection|95
2.16.840.1.113883.3.666.5.2192|Hospital Measures-Wound Care|71
2.16.840.1.113883.3.666.5.2197|Hospital Measures-Prolonged QT Interval|3
2.16.840.1.113883.3.666.5.2202|Hospital Measures-Nursing Home or Ext Fac Transfer|18
2.16.840.1.113883.3.666.5.2203|Hospital Measures-IV Tigecycline|1
2.16.840.1.113883.3.666.5.2204|Hospital Measures-IV Tetracycline|1
2.16.840.1.113883.3.666.5.2205|Hospital Measures-Francisella Tularensis or Yersinia pestis|32
2.16.840.1.113883.3.666.5.2254|Hospital measures - Request of physician|1
2.16.840.1.113883.3.666.5.2256|Any Infection Prior to Anesthesia Concepts|5098
2.16.840.1.113883.3.666.5.2275|Hospital Measures-Cardiac Valve Surgery|130
2.16.840.1.113883.3.666.5.2278|Hospital Measures-MRSA Colonization or Infection|7
2.16.840.1.113883.3.666.5.2282|Hospital measures-Hemodialysis or peritoneal dialysis|29
2.16.840.1.113883.3.666.5.2289|Hospital measures-Acute care hospital encounter|34
2.16.840.1.113883.3.666.5.2310|Hospital Measures-SCIP Urological/Perineal procedures with potential need of indwelling catheters|4967
2.16.840.1.113883.3.666.5.2313|Hospital Measures-SCIP urinary diversion procedures|86
2.16.840.1.113883.3.666.5.2319|Hospital Measures-Respiratory failure acute or chronic|13
2.16.840.1.113883.3.666.5.2348|Hospital Measures-Immunocompromised Therapies|157
2.16.840.1.113883.3.666.5.2365|Hospital Measures-Radiologic Finding-Normal SM-CT|4
2.16.840.1.113883.3.666.5.2486|ICU Locations|11
2.16.840.1.113883.3.666.5.3006|Hospital Measures-ED Locations|19
2.16.840.1.113883.3.666.5.3011|Hospital Measures - AMI|61
2.16.840.1.113883.3.666.5.3013|Hospital Measures-Acute care hospital|12
2.16.840.1.113883.3.666.5.3015|Hospital Measures-Ventricular Assist Device placement|48
2.16.840.1.113883.3.666.5.3022|Hospital Measures-Acute or Evolving MI|51
2.16.840.1.113883.3.666.5.307|Encounter Inpatient|3
2.16.840.1.113883.3.666.5.463|Hospital Measures-IV PO Quinolone Antipneumococcal|8
2.16.840.1.113883.3.666.5.465|Hospital Measures-IV Quinolones Antipneumococcal|3
2.16.840.1.113883.3.666.5.626|Hospital Measures-Aspirin|121
2.16.840.1.113883.3.666.5.672|Hospital Measures-Septicemia|185
2.16.840.1.113883.3.666.5.678|Hospital Measures-Chest xray SM-CT|18
2.16.840.1.113883.3.666.5.680|Hospital Measures-CT scan including chest|7
2.16.840.1.113883.3.666.5.684|Hospital Measures-Acute care hospital|15
2.16.840.1.113883.3.666.5.687|Hospital Measures-Ambulatory surgical center|1
2.16.840.1.113883.3.666.5.693|IV, IM, PO Antimicrobial Medications|455
2.16.840.1.113883.3.666.5.694|Hospital measures-CABG|148
2.16.840.1.113883.3.666.5.696|Hospital Measures - Any infection|2700
2.16.840.1.113883.3.666.5.701|Hospital measures-Other Cardiac Surgery|358
2.16.840.1.113883.3.666.5.703|Hospital measures-Hip arthroplasty|85
2.16.840.1.113883.3.666.5.705|Hospital measures- Colon surgery|498
2.16.840.1.113883.3.666.5.708|Hospital Measures-IV Metronidazole|1
2.16.840.1.113883.3.666.5.710|Hospital measures-Abdominal hysterectomy|22
2.16.840.1.113883.3.666.5.712|Hospital measures-Vaginal hysterectomy|12
2.16.840.1.113883.3.666.5.713|Hospital measures-Vascular surgery|1557
2.16.840.1.113883.3.666.5.719|Hospital Measures-Chronic Wound Care|1
2.16.840.1.113883.3.666.5.720|Hospital Measures-IV or IM Beta lactams|18
2.16.840.1.113883.3.666.5.724|Hospital Measures-IV Colon-Antibiotics|15
2.16.840.1.113883.3.666.5.725|Hospital Measures-IV Ertapenem|2
2.16.840.1.113883.3.666.5.727|Hospital Measures-IV Aminoglycosides|17
2.16.840.1.113883.3.666.5.728|Hospital Measures-IV Aztreonam|3
2.16.840.1.113883.3.666.5.729|Antibiotics for Prophylaxis for Hysterectomy Surgeries|28
2.16.840.1.113883.3.666.5.730|Expired|6
2.16.840.1.113883.3.666.5.735|Hospital Measures-ECG|3
2.16.840.1.113883.3.666.5.736|Hospital Measures-Fibrinolytic Therapy|8
2.16.840.1.113883.3.666.5.748|Hospital Measures-Cardiopulmonary arrest|18
2.16.840.1.113883.3.666.5.752|Hospital Measures-Pneumonia|66
2.16.840.1.113883.3.666.5.758|Hospital Measures-IV Macrolides ICU|7
2.16.840.1.113883.3.666.5.759|Hospital Measures-IV Antipneumococcal/antipseudomonal beta lactams|13
2.16.840.1.113883.3.666.5.760|Hospital Measures-IV or PO Levofloxacin|6
2.16.840.1.113883.3.666.5.765|IV Antimicrobial medication|171
2.16.840.1.113883.3.666.5.766|Hospital measures-IV Vancomycin|12
2.16.840.1.113883.3.666.5.767|Hospital Measures-IV Hysterectomy and Colon Quinolones|5
2.16.840.1.113883.3.666.5.768|Cefuroxime and Cefazolin Antibiotics for IV Administration|13
2.16.840.1.113883.3.666.5.770|Hospital Measures-IV Beta lactams|14
2.16.840.1.113883.3.666.5.772|Hospital Measures-IV or PO Macrolides Non-ICU|38
2.16.840.1.113883.3.666.5.773|Hospital Measures-Bronchiectasis|32
2.16.840.1.113883.3.666.5.774|Hospital Measures-Structural lung disease|86
2.16.840.1.113883.3.666.5.775|Hospital Measures-Chronic bronchitis|19
2.16.840.1.113883.3.666.5.776|Hospital Measures-COPD|7
2.16.840.1.113883.3.666.5.777|Hospital Measures-Interstital lung disease|58
2.16.840.1.113883.3.666.5.779|Hospital Measures-IV or IM Aztreonam|3
2.16.840.1.113883.3.666.5.782|Hospital Measures-Ventilator care|2
2.16.840.1.113883.3.666.5.783|Hospital Measures-Healthcare associated pneumonia|4
2.16.840.1.113883.3.666.5.787|Hospital Measures-Neutrophil count|19
2.16.840.1.113883.3.666.5.801|Hospital Measures-Organ transplant|131
2.16.840.1.113883.3.666.5.803|Hospital Measures-Systemic immunosuppressive therapy|444
2.16.840.1.113883.3.666.5.805|Hospital Measures-Systemic corticosteroid/prednisone therapy|87
2.16.840.1.113883.3.666.5.806|Hospital Measures-Emphysema|40
2.16.840.1.113883.3.666.5.822|Hospital Measures-SCIP urinary diversion|12
2.16.840.1.113883.3.666.5.825|Hospital Measures-Intermittent Catheterization|1
2.16.840.1.113883.3.666.5.827|Hospital Measures-Suprapubic catheter|12
2.16.840.1.113883.3.666.5.829|Hospital Measures-Diuretics RxNorm|70
2.16.840.1.113883.3.666.5.835|IV quinolones|9
2.16.840.1.113883.3.666.5.840|Hospital Measures-IV or PO Tetracyclines|20
2.16.840.1.113883.3.666.5.893|Hospital Measures-IV Clindamycin|4
2.16.840.1.113883.3.666.5.896|Hospital Measures-IV Antipseudomonal quinolones|4
2.16.840.1.113883.3.67.1.101.1.128|Bipolar Disorder|176
2.16.840.1.113883.3.67.1.101.1.246|Personality Disorder|66
2.16.840.1.113883.3.67.1.101.1.254|Dysthymia|11
2.16.840.1.113883.3.67.1.101.1.269|Hepatitis B|43
2.16.840.1.113883.3.67.1.101.1.278|Delivery - Diagnosis|756
2.16.840.1.113883.3.67.1.101.1.279|HBsAg|17
2.16.840.1.113883.3.67.1.101.11.721|Deceased|2
2.16.840.1.113883.3.67.1.101.11.723|PHQ-9 Tool|4
2.16.840.1.113883.3.67.1.101.950|Hospital Measures-Hospital outpatient department|29
2.16.840.1.114222.4.1.214079.1.1.1|Livebirth|16
2.16.840.1.114222.4.1.214079.1.1.3|Newborn Hearing Screen Left|1
2.16.840.1.114222.4.1.214079.1.1.4|Newborn Hearing Screen Right|1
2.16.840.1.114222.4.1.214079.1.1.6|Pass Or Refer|2
2.16.840.1.114222.4.1.214079.1.1.7|Medical Reasons|3
2.16.840.1.114222.4.11.3591|Payer|145
2.16.840.1.114222.4.11.836|Race|6
2.16.840.1.114222.4.11.837|Ethnicity|2
2.16.840.113883.3.67.1.101.3.2444|Major Depression Including Remission|80
2.16.840.113883.3.67.1.101.3.2445|Psych Visit|5
